Keyphrases
Risk Factors
100%
Psoriasis
100%
Treatment Failure
100%
Brodalumab
100%
Obesity
75%
Moderate-to-severe Psoriasis
75%
Tobacco Use
50%
Alcohol
25%
Quality of Life
25%
Clinical Trials
25%
Safe Treatment
25%
Inflammatory Cytokines
25%
Systemic Therapy
25%
Treatment Outcome
25%
Therapeutic Potential
25%
Nicotine
25%
Treatment Options
25%
Response to Treatment
25%
Alcohol Use
25%
Phase III Clinical Trial
25%
Tobacco
25%
High Body Mass Index
25%
Lifestyle Factors
25%
Alcohol Consumption
25%
Interleukin-17 (IL-17)
25%
Psoriasis Pathogenesis
25%
Psoriasis Severity
25%
Biologic Therapy
25%
Chronic Inflammation
25%
Weight-based Dosing
25%
Cell Manufacturing
25%
Lack of Response
25%
Fixed-dose Combination
25%
Skin Clearance
25%
Fully Human
25%
Keratinocyte Cells
25%
Lifestyle-related Risk Factors
25%
Immune Cell Proliferation
25%
Biologic Failure
25%
Medicine and Dentistry
Psoriasis
100%
Post-Hoc Analysis
100%
Brodalumab
100%
Tobacco Use
33%
Clinical Trial
33%
Alcohol Consumption
33%
Quality of Life
16%
Cell Proliferation
16%
Cytokine
16%
Immunocompetent Cell
16%
Side Effect
16%
Body Mass Index
16%
Biological Product
16%
Systemic Therapy
16%
Biological Therapy
16%
Chronic Inflammation
16%
Interleukin 17
16%
Keratinocyte
16%
Pharmacology, Toxicology and Pharmaceutical Science
Psoriasis
100%
Brodalumab
100%
Ethanol
50%
Clinical Trial
33%
Cytokine
16%
Side Effect
16%
Biological Product
16%
Chronic Inflammation
16%
Interleukin 17
16%
Immunology and Microbiology
Brodalumab
100%
Immunocompetent Cell
25%
Cell Proliferation
25%
Proinflammatory Cytokine
25%
Biological Product
25%
Body Mass
25%
Keratinocyte
25%
Interleukin 17
25%